Overall survival interim analysis of a Phase III study of atezolizumab vs best supportive care in resected NSCLC
An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage II-IIIA population (OS HR, 0.71 [95% CI: 0.49, 1.03]), but not in ...
Aug 8, 2022
0
17